Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology

Ann Joy Cheng, Li Chiu Chen, Kun Yi Chien, Yin Ju Chen, Joseph Tung Chieh Chang, Hung Ming Wang, Chun Ta Liao, I. How Chen

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Background: There is no plasma marker for detecting oral cancer, one of the most frequent cancers worldwide. We developed a bead-based affinity- fractionated proteomic method to discover a novel plasma marker for oral cancer. Methods: Affinity purification of heparinized plasma with magnetic beads and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis were used to screen potential oral cancer markers. We compiled MS protein profiles for 57 patients with oral cancer and compared them with profiles from 29 healthy controls. The spectra were analyzed statistically using flexAnalysis™ and Clin-Prot™ bioinformatic software. In each MS analysis, the peak intensities of interest were normalized with an internal standard (adrenocorticotropic hormone 18-39). For identification, affinity bead-purified plasma protein was subjected to MALDI TOF/TOF analysis followed by Mascot identification of the peptide sequences and a search of the National Center for Biotechnology Information protein database. Results: To optimize MALDI-TOF analysis based on the best discriminator of the cancer and control spectra, copper-chelated beads were used for plasma protein profiling. The within- and between-run CVs for assays were

Original languageEnglish
Pages (from-to)2236-2244
Number of pages9
JournalClinical Chemistry
Volume51
Issue number12
DOIs
Publication statusPublished - Dec 2005
Externally publishedYes

Fingerprint

Mouth Neoplasms
Tumor Biomarkers
Proteomics
Technology
Plasmas
Blood Proteins
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Discriminators
Bioinformatics
Biotechnology
Information Centers
Adrenocorticotropic Hormone
Protein Databases
Ionization
Purification
Mass spectrometry
Copper
Assays
Desorption
Proteins

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Cheng, A. J., Chen, L. C., Chien, K. Y., Chen, Y. J., Chang, J. T. C., Wang, H. M., ... Chen, I. H. (2005). Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clinical Chemistry, 51(12), 2236-2244. https://doi.org/10.1373/clinchem.2005.052324

Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. / Cheng, Ann Joy; Chen, Li Chiu; Chien, Kun Yi; Chen, Yin Ju; Chang, Joseph Tung Chieh; Wang, Hung Ming; Liao, Chun Ta; Chen, I. How.

In: Clinical Chemistry, Vol. 51, No. 12, 12.2005, p. 2236-2244.

Research output: Contribution to journalArticle

Cheng, AJ, Chen, LC, Chien, KY, Chen, YJ, Chang, JTC, Wang, HM, Liao, CT & Chen, IH 2005, 'Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology', Clinical Chemistry, vol. 51, no. 12, pp. 2236-2244. https://doi.org/10.1373/clinchem.2005.052324
Cheng, Ann Joy ; Chen, Li Chiu ; Chien, Kun Yi ; Chen, Yin Ju ; Chang, Joseph Tung Chieh ; Wang, Hung Ming ; Liao, Chun Ta ; Chen, I. How. / Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. In: Clinical Chemistry. 2005 ; Vol. 51, No. 12. pp. 2236-2244.
@article{1533713bb2e44a24863ba170212ffc66,
title = "Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology",
abstract = "Background: There is no plasma marker for detecting oral cancer, one of the most frequent cancers worldwide. We developed a bead-based affinity- fractionated proteomic method to discover a novel plasma marker for oral cancer. Methods: Affinity purification of heparinized plasma with magnetic beads and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis were used to screen potential oral cancer markers. We compiled MS protein profiles for 57 patients with oral cancer and compared them with profiles from 29 healthy controls. The spectra were analyzed statistically using flexAnalysis™ and Clin-Prot™ bioinformatic software. In each MS analysis, the peak intensities of interest were normalized with an internal standard (adrenocorticotropic hormone 18-39). For identification, affinity bead-purified plasma protein was subjected to MALDI TOF/TOF analysis followed by Mascot identification of the peptide sequences and a search of the National Center for Biotechnology Information protein database. Results: To optimize MALDI-TOF analysis based on the best discriminator of the cancer and control spectra, copper-chelated beads were used for plasma protein profiling. The within- and between-run CVs for assays were",
author = "Cheng, {Ann Joy} and Chen, {Li Chiu} and Chien, {Kun Yi} and Chen, {Yin Ju} and Chang, {Joseph Tung Chieh} and Wang, {Hung Ming} and Liao, {Chun Ta} and Chen, {I. How}",
year = "2005",
month = "12",
doi = "10.1373/clinchem.2005.052324",
language = "English",
volume = "51",
pages = "2236--2244",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "12",

}

TY - JOUR

T1 - Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology

AU - Cheng, Ann Joy

AU - Chen, Li Chiu

AU - Chien, Kun Yi

AU - Chen, Yin Ju

AU - Chang, Joseph Tung Chieh

AU - Wang, Hung Ming

AU - Liao, Chun Ta

AU - Chen, I. How

PY - 2005/12

Y1 - 2005/12

N2 - Background: There is no plasma marker for detecting oral cancer, one of the most frequent cancers worldwide. We developed a bead-based affinity- fractionated proteomic method to discover a novel plasma marker for oral cancer. Methods: Affinity purification of heparinized plasma with magnetic beads and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis were used to screen potential oral cancer markers. We compiled MS protein profiles for 57 patients with oral cancer and compared them with profiles from 29 healthy controls. The spectra were analyzed statistically using flexAnalysis™ and Clin-Prot™ bioinformatic software. In each MS analysis, the peak intensities of interest were normalized with an internal standard (adrenocorticotropic hormone 18-39). For identification, affinity bead-purified plasma protein was subjected to MALDI TOF/TOF analysis followed by Mascot identification of the peptide sequences and a search of the National Center for Biotechnology Information protein database. Results: To optimize MALDI-TOF analysis based on the best discriminator of the cancer and control spectra, copper-chelated beads were used for plasma protein profiling. The within- and between-run CVs for assays were

AB - Background: There is no plasma marker for detecting oral cancer, one of the most frequent cancers worldwide. We developed a bead-based affinity- fractionated proteomic method to discover a novel plasma marker for oral cancer. Methods: Affinity purification of heparinized plasma with magnetic beads and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis were used to screen potential oral cancer markers. We compiled MS protein profiles for 57 patients with oral cancer and compared them with profiles from 29 healthy controls. The spectra were analyzed statistically using flexAnalysis™ and Clin-Prot™ bioinformatic software. In each MS analysis, the peak intensities of interest were normalized with an internal standard (adrenocorticotropic hormone 18-39). For identification, affinity bead-purified plasma protein was subjected to MALDI TOF/TOF analysis followed by Mascot identification of the peptide sequences and a search of the National Center for Biotechnology Information protein database. Results: To optimize MALDI-TOF analysis based on the best discriminator of the cancer and control spectra, copper-chelated beads were used for plasma protein profiling. The within- and between-run CVs for assays were

UR - http://www.scopus.com/inward/record.url?scp=28044447188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044447188&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2005.052324

DO - 10.1373/clinchem.2005.052324

M3 - Article

C2 - 16239339

AN - SCOPUS:28044447188

VL - 51

SP - 2236

EP - 2244

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 12

ER -